{"name":"Elizabeth Berry-Kravis","slug":"elizabeth-berry-kravis","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"5-Hydroxytryptophan","genericName":"5-Hydroxytryptophan","slug":"5-hydroxytryptophan","indication":"Depression","status":"marketed"}]}],"pipeline":[{"name":"5-Hydroxytryptophan","genericName":"5-Hydroxytryptophan","slug":"5-hydroxytryptophan","phase":"marketed","mechanism":"5-Hydroxytryptophan (5-HTP) is a precursor to serotonin that increases central nervous system serotonin levels by crossing the blood-brain barrier and being converted to serotonin via aromatic amino acid decarboxylase.","indications":["Depression","Anxiety","Sleep disorders","Fibromyalgia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQTkpfXzA4T2VaNmVWeUg0SHpLQmJZbGVzTzRJYVpWbTd3ZDZ5eVdFUEtnQ25YYjNyMmhTTm9iYm5idjFRNDVsaWlkZ1lqeGdWcWJUMDUtMHk4ZHhJRkp5N1JnNmpPMFJ1ZWI4NjM2NzNLMUk4QmFweXVyaWljLVVDRjVsdnJ3SlVoWnhVUlp4TlBabFRqcFNrQ2ZDVEoxbkN4UHZ1dmhuNThQdDIyajk2eUx3V3dhZ0hxXzhQZldaS3BkVC1QdzhVSV94STF4T1pMSmRZSW5lNkJ2S1JsR2I5M2tLdEg0RW1fT05vSW0wUnVzeUZzS0xkbFdJOExuR1laYllFaU9mNjA0dUdueWxucklaaHNacXhMaFVMTmd3WQ?oc=5","date":"2025-10-09","type":"regulatory","source":"businesswire.com","summary":"Data Analyses Show Benefit for Individuals With Infantile-Onset Niemann-Pick Disease Type C Treated With Investigational Drug Adrabetadex - businesswire.com","headline":"Data Analyses Show Benefit for Individuals With Infantile-Onset Niemann-Pick Disease Type C Treated With Investigational","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9UcDhyNkNlZWdLMzJBVXFCYkRpRGl0U29uZVU3RXpCbUN5ZkVPREV3MDcwaGR5aTN5TWFaYlFxNXdqY09rbjFlZG1OeTRzQ2hUeVlR?oc=5","date":"2025-04-15","type":"deal","source":"FirstWord Pharma","summary":"Roche's castoff Angelman drug gets second life in Oak Hill deal - FirstWord Pharma","headline":"Roche's castoff Angelman drug gets second life in Oak Hill deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE1GTWNIajFrMGFKZ1Z1QVZpRjVLU2VqV3VfdnlpMV9lNFlSVkpWTVQtTmhUUFFvcGZiMzA2dUFNZk5DZ0RsSjBFS0hUZ0NUSm9kZGNJeFcxY1MxS0d6cEZQclVFZ0lUeThZUS14N3pEb0FNYTA?oc=5","date":"2025-04-15","type":"pipeline","source":"The Pharma Letter","summary":"Roche's rugonersen finds a new home - The Pharma Letter","headline":"Roche's rugonersen finds a new home","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQYWVmV1F4Vzl6dDVLemVDaGpmLWVFOVQ2c1dVQlM2N2dHRVF4WFBPb29qaHpRUlcwb2tjNGJUSC1HNkMzV3U0R3pQYWU1bmg1bWVKdFhDRjBaS1c0cl9NakZEMEkzMjRPZzgxbUx1QlNqZ2x0VEVOaTZNTjJPWG9pYVZyZG5xREJzU0NTNjRlaGtpaS1hMXp6OFR1RUttdw?oc=5","date":"2024-08-06","type":"trial","source":"statnews.com","summary":"'Jerking families around': Canceled Roche rare disease trial devastates parents, angers researchers - statnews.com","headline":"'Jerking families around': Canceled Roche rare disease trial devastates parents, angers researchers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOT1F0N2ZrdU1YMnYwbzZ1UkFVVi1xcjBIMVo1YXpXcjBZRXJ2UjZ1bFYtSDlVMUN1RjF3blhrSjU3RzJmbE82cVV0ZjdJeVZTTFEzMVFLM3BoSVIxdWlPdnZ4aUdBWE0wUXJIX3NYaGtHdmM3VEI3bWN4b291b3FuakNlYjFPd3ZQanRpaGdBRkNMaThidDQtQUtPcHJGLWUxamc?oc=5","date":"2023-12-19","type":"trial","source":"Biotech Dispatch","summary":"Neuren Pharmaceuticals announces top-line results of Phase 2 NNZ-2591 trial - Biotech Dispatch","headline":"Neuren Pharmaceuticals announces top-line results of Phase 2 NNZ-2591 trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9wenBQcTZOTUM1MXZKSEx4amRIVEMzUTk3YlFRQlI5Zm43b1lqRW1KUnhqMGwzeGQzQnhHUkJaUDJDaUpySU5jRWJoOFl6SEVoS240cElWVGd3OFdUbGhR?oc=5","date":"2023-06-08","type":"trial","source":"nature.com","summary":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study - nature.com","headline":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNN2FNNnBjRVZVbFhJbnZFNUdRLTlFY0FZU25OdTJ4ZThvTDBpcUdVdlRLQ2pNQnlWUm9yWExxQWh2SDZxX0RNTkFnS3UtMlFVMWJjdFIzUHJNQ25OVnNwNllHQjdmY0R5NGwzaFRMQlRSaVd5VW1KX3pUV0RKLTRleWt3d1QwSUFPYllsUnF3UWZIcXlCZ3NKUkV3?oc=5","date":"2022-08-19","type":"trial","source":"Fragile X News Today","summary":"Arbaclofen Improved Behavior of Almost Half of Children in Phase 3 Trial - Fragile X News Today","headline":"Arbaclofen Improved Behavior of Almost Half of Children in Phase 3 Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNaTFyejdrZ1Z3QW80Rmp4NHY3emZwTHg2aXNpY3I5cWRXS2JGZERMcm5KYVQ2bmF5UnBNMHd3MmQzSm5SRkExYmlPTXNwYzBIbHFrdkIxRkg0b2g5a3R3dDI4NnNyWmlJS3hFa2tueE9XOGVTZXpMX3dXeGEwN1NWb1ZGdzZPa1MzeFJmN3puSGt5MTh2aWUyNkV3U1lYckF0QmNLNFMtYV9PNlhmemkybU1SbmJzOXljaWVDTGpxa0tuX0F0YXFfQlRQaUtTVjRCRFZWNkpKMGNXT0ltZ25Ha3lxdDBmaHR6NlN3Zkh0bDF5ZUxubldBbkg1R245b0JJTUt5SVZuTVN3T3ZLRnc?oc=5","date":"2019-02-22","type":"pipeline","source":"Proactive Investors","summary":"Zynerba Pharmaceuticals’ quest for CBD gel to treat Fragile X syndrome ventures where big pharma fears to tread - Proactive Investors","headline":"Zynerba Pharmaceuticals’ quest for CBD gel to treat Fragile X syndrome ventures where big pharma fears to tread","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQYmVNUFo2eExXd3ZqbUZCUjNGbmlOTVdOTFVOUzJTTHhlUGNielJsQjBIVzA0UWhfblZoY2U3MjBtU2RIWWZab1NQZzQ0WS1BTTRBRllETlo3Smp4Yy1WUUg3Zm1nMEktTVlINDNoT1J6Um04amdzTVB5cHZwSDExVzNiblpiMzlUaEJJ?oc=5","date":"2014-05-06","type":"pipeline","source":"The Transmitter","summary":"Drug company halts tests of fragile X drug - The Transmitter","headline":"Drug company halts tests of fragile X drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQTGhiWUI3Y3FtUzhLaldGeVEybWVzSEp2eUNUYm93SmdvMXFXbFhtTmVZdGFDT2JKWlNaeWtuN21JcE5pdHFOY3dPTmNCRDlZemhORHJTMlJhd0ZOZFJnS3YtSEJ2X1hGUFJZRkhTWHh6NkFMRG9EMVNYWjhDZ0Y2Y0JJM0pkanNsdnUzSA?oc=5","date":"2010-06-29","type":"pipeline","source":"The Transmitter","summary":"Pharma companies set their sights on autism - The Transmitter","headline":"Pharma companies set their sights on autism","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}